42 results on '"Lakhwani, Sunil"'
Search Results
2. Identification of patient-reported outcomes measures (PROMs) and patient-reported experiences measures (PREMs) in Gaucher disease in Spain
3. Fostamatinib effectiveness and safety for immune thrombocytopenia in clinical practice
4. The Cardiovascular Event Risk Associated with Tyrosine Kinase Inhibitors and the Lipid Profile in Patients with Chronic Myeloid Leukemia
5. Measurable residual disease by mass spectrometry and next-generation flow to assess treatment response in myeloma
6. Safety and efficacy of asciminib treatment in chronic myeloid leukemia patients in real-life clinical practice
7. PB1900: COMBINED TREATMENT WITH VENETOCLAX PLUS HYPOMETHYLATING AGENT OR CYTARABINE VERSUS TREATMENT WITH HYPOMETHYLATING AGENT ALONE IN ACUTE MYELOID LEUKEMIA IN POOR PROGNOSIS PATIENTS.
8. PB2323: R-ESHAP VS R-ICE AS RESCUE TREATMENT IN DIFFUSE LARGE B-CELL LYMPHOMA. A SINGLE-CENTEREXPERIENCE.
9. PB2210: COMPARISON OF THREE PROGNOSTIC SCORING SYSTEMS FOR THE RISK OF THROMBOSIS IN ESSENTIAL THROMBOCYTHEMIA: ANALYSIS OF 190 PATIENTS AT THE UNIVERSITY HOSPITAL OF THE CANARY ISLANDS (1990-2022)
10. PB2353: PROGNOSTIC VALUE OF TIME FROM SYMPTOMS BEGIN TO START TREATMENT IN DIFFUSE LARGE B-CELL LYMPHOMA
11. Toxicity of Asciminib in Real Clinical Practice: Analysis of Side Effects and Cross-Toxicity with Tyrosine Kinase Inhibitors
12. Recovery of Uninvolved Heavy/Light Chain Pair Immunoparesis during Maintenance Is an Independent Prognostic Factor for Multiple Myeloma and Could Complement Prognosis Value of Minimal Residual Disease
13. Real-World Data Analysis of the Molecular Response Kinetics within the Two First Years of the RELMC-NOVA Study in Newly Diagnosed Spanish CML-CP Patients Treated with Tirosin Kinasa Inhibitors (TKIs) in First Line
14. Immunoparesis Recovery in Transplant-Ineligible Newly Diagnosis Multiple Myeloma Patients: An Independent Prognosis Factor That Could Complement Prognostic Value of Minimal Residual Disease
15. Toxicity of Asciminib in Real Clinical Practice; Analysis of Side Effects and Cross-Intolerance with Tyrosine Kinase Inhibitors
16. Intramuscular Anti‐D treatment for immune thrombocytopenia: A single centre experience
17. Thrombopoietin receptor agonist switch in adult primary immune thrombocytopenia patients: A retrospective collaborative survey involving 4 Spanish centres
18. sj-docx-1-opp-10.1177_10781552211052535 - Supplemental material for Imatinib plasma levels in patients with chronic myeloid leukaemia under routine clinical practice conditions
19. Intramuscular Anti‐D treatment for immune thrombocytopenia: A single centre experience.
20. Imatinib plasma levels in patients with chronic myeloid leukaemia under routine clinical practice conditions.
21. Asciminib in Real-Life Clinical Practice, Safety and Efficacy Profile in Chronic Myeloid Leukemia Pretreated Patients
22. Imatinib plasma levels in patients with chronic myeloid leukaemia under routine clinical practice conditions
23. Mucosa-Associated Lymphoid-Tissue Lymphoma of the Descending Colon in a Patient with Blastocystis hominis Infection: A Case Report and Review of Literature
24. Sustained Recovery of Uninvolved Heavy/Light Chain Pair Immunoparesis during Maintenance Discriminates Patients with Sustained Negative Minimal Residual Disease
25. Biological Factors Associated with Treatment-Free Remission in Clinical Practice: Data from the Canarian Registry of CML
26. Caplacizumab As New Paradigm-Changing Therapy for Patients with Autoimmune Thrombotic Thrombocytopenic Purpura (aTTP): Real-World Data from TTP Spanish Registry
27. Safety and Efficacy Profile of Asciminib As Treatment in Chronic Myeloid Leukemia Patients after Several Tyrosine-Kinase Inhibitors Failure
28. Acute Compartment Syndrome of the forearm in a patient undergoing coronary artery bypass surgery
29. Treatment with daratumumab in patients with relapsed/refractory AL amyloidosis: a multicentric retrospective study and review of the literature
30. Early Death in Multiple Myeloma. Analysis of Patients in Real-World Practice
31. Valor pronóstico de la recuperación de la inmunoparesia en el mieloma múltiple
32. Bone marrow trephine biopsy in Hodgkin's lymphoma. Comparison with PET–CT scan in 65 patients
33. Biopsia de médula ósea en el linfoma de Hodgkin. Comparación con la PET-TC en 65 pacientes
34. Outbreak of vancomycin-resistant enterococcus on a haematology ward: management and control
35. A Conservative Tailoring of Ponatinib Dose in Chronic Myeloid Leukemia Patients Can Diminish Adverse Events While Maintaining Efficacy
36. Outbreak of vancomycin-resistant enterococcuson a haematology ward: management and control
37. Factor neurotrófico derivado del cerebro y primeros episodios psicóticos. Estudio pronóstico de un año.
38. Importancia del diagnóstico precoz de la policitemia vera: experiencia en un centro
39. Valor pronóstico de la amplitud de distribución eritrocitaria al diagnóstico en el linfoma difuso de células grandes B
40. Avatrombopag in immune thrombocytopenia: A real-world study of the Spanish ITP Group (GEPTI).
41. Recovery of uninvolved heavy/light chain pair immunoparesis in newly diagnosed transplant-eligible myeloma patients complements the prognostic value of minimal residual disease detection.
42. Brain-Derived Neurotrophic Factor (BDNF) and First-Episode Psychosis. A longitudinal one-year prognosis study.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.